Predictive Role of Computed Tomography Texture Analysis in Patients with Metastatic Urothelial Cancer Treated with Programmed Death-1 and Programmed Death-ligand 1 Inhibitors (European Urology Oncology)

We investigated whether computed tomography (CT) texture analysis, a biomarker of tumor heterogeneity, could predict progression-free survival in patients with metastatic urothelial cancer treated with programmed death-1 and programmed death-ligand 1 (PD-1/PD-L1) inhibitors. CT texture analysis helps predict durability of response soon after starting PD-1/PD-L1 inhibitors.